Compare Ginkgo Bioworks Holdings Inc (DNA) vs Fox Corp Class B (FOX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Fox Corp Class B — how do they compare? Ginkgo Bioworks Holdings Inc trades at $9.04 (market cap $590.53M), while Fox Corp Class B trades at $50.78 (market cap $21.85B). The key difference: Fox Corp Class B is far larger — about 37× Ginkgo Bioworks Holdings Inc's market cap, and Fox Corp Class B pays a 1.13% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | FOX | |
|---|---|---|
Market Cap | $590.53M | $21.85B |
Sector | Health | Media |
52-Week High | $16.14 | $67.76 |
52-Week Low | $5.48 | $44.39 |
Enterprise Value | $627.78M | $25.83B |
Dividend Yield | — | 1.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
FOX trades at $50.22, up 3.02% with bullish technical signals and strong earnings beats. Recent Q1 2026 EPS of $1.32 exceeded expectations by 33.6%, continuing a pattern of outperformance. The company shows improved cash flow with 2025 operating cash flow reaching $3.32 billion, while revenue grew to $16.30 billion. Technical indicators show mixed signals with RSI at neutral levels but ADX suggesting strong trend momentum.
The outlook remains positive with analyst price targets suggesting 27-39% upside potential. Key risks include competitive pressures in streaming and potential volatility from the recent Roku acquisition. Wall Street sentiment is cautiously optimistic with 43% buy ratings, though the stock faces near-term execution challenges with projected 2026 cash flow turning negative.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Fox Corp Class B
Fox represents the assets not sold to Disney by the predecessor firm, Twenty First Century Fox. The remaining assets include Fox News, the FOX broadcast network, FS1 and FS2, Fox Business, Big Ten Network, 28 owned and operated local television stations of which 17 are affiliated with the Fox Network, and the Fox Studios lot. The Murdoch family continues to control the successor firm, which represents a large-scale bet on the value of live sports and news in the U.S. market.
Read more on FOX →
